Allergy Therapeutics (LON:AGY) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Shares of Allergy Therapeutics plc (LON:AGY) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 10.60 and traded as low as GBX 7.67. Allergy Therapeutics shares last traded at GBX 8, with a volume of 47,689 shares.

Allergy Therapeutics Price Performance

The stock’s 50-day moving average price is GBX 9.85 and its 200-day moving average price is GBX 10.58. The company has a market capitalization of £504.70 million, a price-to-earnings ratio of -8.22, a price-to-earnings-growth ratio of -30.70 and a beta of 0.89. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY) last announced its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%.The company had revenue of GBX 3,628 million for the quarter. Equities research analysts anticipate that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.